Section
A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.
A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc
A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.
A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.
A single-center retrospective study found unexpectedly high rates of concurrent endometrial carcinoma and Mayo-criteria risk features among patients with atypical endometrial hyperplasia in a predominantly racial and ethnic minority populat
A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and th
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.
A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.
A cancer program quality improvement initiative reached a 100% smoking-status ask rate through an electronic hard stop, but assistance for identified smokers remained inconsistent, underscoring the implementation gap between screening and e
This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.
Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
A retrospective cohort study suggests that preoperative tumor burden, extent of tongue resection, and degree of volume restoration are strongly associated with swallowing and speech outcomes after glossectomy.
In the SANO cohort, 85% of patients with uncertain post-chemoradiotherapy response had residual tumor at esophagectomy, supporting surgery for most, while highlighting a notable complete response subgroup among squamous cell carcinoma with
This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microe
A Gut study links PTEN deficiency in MSS colorectal cancer to NRF2-driven autophagic loss of MHC-I, impaired CD8+ T-cell surveillance, and resistance to anti-PD-1 therapy, while identifying NRF2 inhibition as a potential sensitizing strateg
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
In a prospective multicenter cohort, P85-Ab achieved 93.0% sensitivity and 97.3% specificity for suspected nasopharyngeal carcinoma, outperforming conventional EBV serologies in outpatient practice.
This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.
